High content compound screening has identified Androgen receptor – Transcription Intermediary Factor 2 (TIF2) disrupters for prostate cancer [37], menin-mixed lineage leukemia 1 (MLL1) disrupters for leukemia [38, 39], B-cell lymphoma 6 (BCL6) – BCL6 corepressor (BCOR) disrupters for treatment of diffuse large B-cell lymphomas [40], Rictor – mTOR blockers for glioblastoma [41] and P53 – MDM2 inhibitors for a range of treatment resistant cancer types [42, 43]. Here, KMT2A is linked to leukemia.